NCT00359632TerminatedPhase 3
Prospective Study Of Ophthalmologic Function In Patients Receiving Linezolid For Six Weeks Or Greater
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Terminated
- Sponsor
- Pfizer
- Enrollment
- 34
- Locations
- 12
- Primary Endpoint
- Percentage of Participants With an Adverse Event
Study Overview
Brief Summary
To understand and characterize the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for six weeks or longer for the development of signs or symptoms of visual disturbance or eye disorders.
Detailed Description
Characterize Optic Side Effect
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male and female subjects who are 18 years of age or older.
- •Subjects in Treated Group:
- •Subjects must have received linezolid 600 mg BID for six weeks or greater and be currently on drug (or have received linezolid within 7 days of baseline evaluation).
- •Subjects who have current signs or symptoms compatible with linezolid toxicity (i.e. optic or peripheral neuropathy) may be enrolled in the study if they are on linezolid at time of baseline evaluation (or have received linezolid within 7 days of baseline evaluation).
- •Linezolid may be discontinued at any time at the primary physician's discretion and remain on the study.
- •Women of childbearing potential must use adequate contraception
- •Subjects in Control Group:
- •Subjects will have a diagnosis similar to patients in the treated group and similar important co-morbidities and epidemiologic factors if possible.
Exclusion Criteria
- •Subject in Treated Group:
- •Subjects with a known presence of optic or peripheral nerve damage due to another illness, condition or medication.
- •Subjects with a pre-existing or a diagnosis at time of screening visit of an ophthalmologic condition that would adversely affect the study testing protocol (e.g. dense cataracts, macular degeneration, retinitis pigmentosa).
- •Subjects who are currently receiving or anticipated to receive another medication, antibiotic or other, that has known potential to produce ocular or neurologic toxicity indistinguishable from that caused by linezolid or lactic acidosis.
- •Subjects with a history of significant exposure, in the opinion of the investigator and with prior discussion with the medical monitor, to medications known to produce optic or peripheral neuropathy.
- •Subjects with an active communicable disease (i.e., tuberculosis assessed as currently communicable) and subjects on active treatment for tuberculosis or other mycobacterial disease that include drugs that have known potential to produce ocular or neurologic toxicity.
- •Subjects with severe liver disease or abnormal liver function test.
- •Subjects in Control Group:
- •Subjects must not currently be taking linezolid or have received it for more than 7 days at any time.
- •Subjects with a known presence of optic or peripheral nerve damage due to another illness, condition or medication.
- •Subjects with a pre-existing or a diagnosis at the screening visit of an ophthalmologic condition that would adversely affect the study testing protocol (e.g. dense cataracts, macular degeneration, retinitis pigmentosa).
- •Subjects who are currently receiving another medication, antibiotic or other, that has known potential to produce ocular or neurologic toxicity indistinguishable from that caused by linezolid or lactic acidosis.
- •Subjects with a history of significant exposure, in the opinion of the investigator and with prior discussion with the medical monitor, to medications known to produce optic or peripheral neuropathy.
- •Subjects with an active communicable disease (i.e., tuberculosis assessed as currently communicable) and subjects on active treatment for tuberculosis or other mycobacterial disease that include drugs that have known potential to produce ocular or neurologic toxicity.
Arms & Interventions
Linezolid
Experimental
Subjects have received at least 6 weeks of linezolid therapy (600 mg BID). Continued duration of linezolid treatment is based on treating physician's benefit/risk assessment. A matching control who did not receive linezolid will be selected for each linezolid treated subject.
Intervention: Zyvox - linezolid (Drug)
Matched control
Active Comparator
Control subjects individually matched to linezolid subjects (on age, gender and type of infection) who received at least 6 weeks of antibiotics other than linezolid. Control group assessed only at baseline visit to assess presence of background abnormalities in the study test panel.
Intervention: Matched control (Drug)
Outcomes
Primary Outcomes
Percentage of Participants With an Adverse Event
Time Frame: Through and including 28 calendar days after the last administration of the investigational product
Secondary Outcomes
- Percentage of Participants by Clinical Outcome of Infection at End of Study(At End of Study visit)
Investigators
Study Sites (12)
Loading locations...
Similar Trials
Completed
Not Applicable
Optic Nerve and Retinal Functions With BevacizumabChoroidal Neovascular MembraneNCT01361828Cairo University45
Unknown
Not Applicable
Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.Neurofibromatosis Type 1NCT02078401Universitaire Ziekenhuizen KU Leuven200
Completed
Not Applicable
Eye Evaluation in Patients With PCOSPCOSNCT01950832Gökhan Açmaz124
Enrolling By Invitation
Not Applicable
Electrical Stimulation of the Optic Nerve in Patients With Glaucoma.GlaucomaNCT06693882Glaucoma Center of San Francisco50
Recruiting
Not Applicable
Changes in Optic nerve sheath diameter in patients undergoing robotic renal transplant.CTRI/2020/09/027930O SPONSOR